Veracyte | VCYT - Net Income


Veracyte reported $28.71M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Agenus USD -10.63M 74.49M Dec/2025
Agilent USD 305M 129M Dec/2025
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
Bruker USD 3.5M 22.5M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Illumina USD 134M 200M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Laboratory Of America USD 277.8M 113.1M Mar/2026
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Siemens EUR 2.03B 3M Mar/2026
Sonic Healthcare AUD 236.68M 82.29M Dec/2024
Thermo Fisher Scientific USD 1.65B 313M Mar/2026
Veracyte USD 28.71M 12.44M Mar/2026
Waters USD -72M 297.21M Mar/2026